Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Ozempic and Wegovy use fixed-dose pens (0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg for Ozempic)
"Women shouldn't wait until symptoms become unbearable to seek help," says Gilberg
, ,
2024-Present: Expanded Indications Under Investigation Multiple ongoing trials evaluate tirzepatide for: SUMMIT: Cardiovascular outcomes in obesity with heart failure SYNERGY-NASH: Metabolic dysfunction-associated steatohepatitis showing significant fibrosis improvement [6] SURMOUNT-OSA: Obstructive sleep apnea treatment SURPASS-CVOT: Major adverse cardiovascular events in diabetes with established CVD [7] Molecular Characteristics Landmark Clinical Findings Weight Loss Tirzepatide produces the most substantial weight reductions ever documented for a pharmacological obesity intervention: SURMOUNT-1 (non-diabetes): Mean weight loss of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) vs
doi: 10.13227/J.HJKX.202312236 100
US$ 27.36
US$ 24.21
US$ 23.10
US$ 20.25
US$ 28.66
US$ 29.01
US$ 26.06
US$ 29.80
